Neuphoria Therapeutics Inc. (NASDAQ:NEUP) (Neuphoria or Company), "), a clinical-stage biotechnology developing impactful treatments for neuropsychiatric disorders, bringing new hope and tangible improvements to patients' lives, announced today that it will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York City on Monday, March 3rd, 2025.
Spyros Papapetropoulos MD, PhD, President and Chief Executive Officer will be joined by Neuphoria's board of directors, members of the management team, and advisors.
English